GlycoNex Incorporation (TPEX:4168)

Market Cap	2.43B +33.1%
Revenue (ttm)	37.86M +157.5%
Net Income	-235.23M
EPS	-2.16
Shares Out	108.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	247,159
Average Volume	204,526
Open	22.85
Previous Close	22.85
Day's Range	22.30 - 23.15
52-Week Range	17.55 - 30.95
Beta	0.56
RSI	39.81
Earnings Date	May 13, 2026

About GlycoNex Incorporation

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company’s development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed antibody drug currently under the lead optimization stage; and GNX1021, a first-in-class antibody–drug conjugate currently under preclinical stage. It is a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4168

Financial Performance

In 2025, GlycoNex Incorporation's revenue was 37.86 million, an increase of 157.54% compared to the previous year's 14.70 million. Losses were -235.23 million, 2.40% more than in 2024.